Early Medical Affairs Collaboration Secures Promotional Content Integrity

 

Strong alignment between brand and medical affairs teams is essential in today’s evolving promotional content landscape. Ensuring seamless collaboration can enhance content quality and efficiency. Effective collaboration between these teams can significantly streamline processes and improve the quality of promotional materials​

What are the key strategies to foster better collaboration between brand and medical affairs teams in 2024?

On this episode of Amend & Progress by Vodori, host Annalise Ludtke discusses with Grace Macalino, a scientific strategy and medical affairs consultant, the nuances of improving the relationship between brand and medical affairs teams. This discussion covers best practices for collaboration, challenges faced during promotional content review, and strategies to ensure rigorous and compliant content creation.

Main Points of Conversation:

  • Early Involvement: Bringing medical affairs into the content development process early can prevent many issues down the line, ensuring that scientific rigor and compliance are maintained from the start.
  • Clear Communication: Establishing open lines of communication and mutual understanding between the teams can help manage expectations and align goals effectively.
  • Claims Management: Developing a comprehensive claims matrix early in the campaign planning process can streamline promotional content review and reduce unnecessary revisions.

Grace Macalino is a seasoned consultant in scientific strategy and medical affairs. With a background in epidemiology, she has dedicated her career to bridging the gap between scientific research and commercial strategy. Grace has worked with numerous pharmaceutical companies to enhance their medical affairs strategies and improve collaboration with brand teams.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…